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Abstract 
Background: Endothelial dysfunction has been suggested as a possible causal link between hyperglycemia and 
microvascular complications in diabetes mellitus. The effect of metformin on endothelial progenitor cells (EPCs) is still 
unclear. This study was designed to test the hypothesis that metformin could accelerate wound healing by improving 
the impaired EPC functions in streptozotocin‑induced diabetic mice.
Methods: Streptozotocin (STZ, 60 mg/kg/d × 5 d, i.p.) was injected to induce type 1 diabetes in male C57BL/6 mice. 
Mice were treated with metformin (250 mg/kg/d, i.g.) for consecutive 14 days. Wound closure was evaluated by 
wound area and number of CD31 stained capillaries. Functions of bone marrow‑endothelial progenitor cells (BM‑
EPCs) were assessed by tube formation and migration assays, and expression of AMP‑activated protein kinase (AMPK) 
and endothelial nitric oxide synthase (eNOS) was determined by western blot analysis.
Results: Metformin accelerated wound closure and stimulated angiogenesis in diabetic mice. The number of circu‑
lating EPCs was increased significantly in metformin treated diabetic mice. Abilities of tube formation and migration 
of BM‑EPCs were impaired in diabetic mice, which were improved by metformin. Expression of both phosphorylated‑
AMPK and phosphorylated‑eNOS was significantly increased, and nitric oxide (NO) production was enhanced by 
metformin in BM‑EPCs of diabetic mice. In vitro, metformin improved impaired BM‑EPC functions, and increased 
phosphorylated‑eNOS expression and NO production in cultured BM‑EPCs caused by high glucose, which was pre‑
vented by the AMPK inhibitor compound C.
Conclusions: Our results suggest that metformin could improve BM‑EPC functions in STZ‑induced diabetic mice, 
which was possibly dependent on the AMPK/eNOS pathway.
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Background
Diabetes mellitus is the most serious, chronic metabolic 
disorder, which is characterized by hyperglycemia, and 
affecting more than 400 million people worldwide with 
a predicted >50  % increase in 2030 [1, 2]. In particular, 
microvascular and macrovascular disease, one of the 
main complications of diabetes, has been proposed as an 
important risk factor for the death of diabetic patients [3, 
4].
Endothelial dysfunction is not only strongly associated 
with risk of vascular disease, but also the inner cause of 
impaired wound healing ability [5, 6]. Endothelial pro-
genitor cells (EPCs) play a primary role in angiogenesis 
but are functionally impaired in diabetes, which may con-
tribute to endothelial dysfunction [7]. EPCs are vital for 
the vascular protection and angiogenesis [8]. In patients 
with diabetes, circulating EPCs number is decreased and 
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EPC functions is impaired [9, 10], which are believed to 
be one of the pathogenesis of vascular complications in 
diabetes, as manifested by impaired wound healing.
Metformin is a biguanide derivative, which is the 
most widely prescribed oral hypoglycaemic drug for the 
management of type 2 diabetes mellitus [11, 12]. Sev-
eral studies have focused on the effects of metformin on 
EPCs in patients with diabetes, and found that patients 
with type 2 diabetes treated with metformin had signifi-
cantly increased number of circulating EPCs [13]. Recent 
studies demonstrated that activation of AMP-activated 
protein kinase (AMPK) partly mediated the therapeu-
tic effects of metformin, which stimulated ischemia-
induced revascularization in the ischemic hindlimb 
mice model [14–16]. Furthermore, studies found that 
clinically relevant concentrations of metformin acti-
vated AMPK in cultured endothelial cells (ECs) [17–21]. 
AMPK is a well conserved heterotrimer protein com-
prising α, β, and γ subunits, each of which has 2 or 3 
genes encoding [22]. Findings support the notion that 
AMPK was a new regulator of angiogenesis, which was 
specifically required for ECs migration and differentia-
tion under hypoxia conditions [23, 24]. In addition, it 
was found that activated AMPK could directly phospho-
rylate endothelial nitric oxide synthase (eNOS) in ECs 
and promote endothelial function [25–28]. However, 
little information exists regarding the role of metformin 
on EPC functions under diabetic conditions. Thus, our 
study tested the hypothesis that metformin could accel-
erate wound healing, at least in part, by improving the 
angiogenic functions of EPCs with an AMPK related 
pathway in diabetic mice.
Methods
Animals and treatments
Male C57BL/6 mice (6w, 18–20  g), purchased from 
the Sino-British SIPPR/BK Lab Animal Ltd (Shanghai, 
China), were housed in controlled conditions (tem-
perature: 23  ±  2  °C; lighting: 8:00–20:00) and received 
a standard mouse chow and tap water ad  libitum. All 
the animals used in this work received humane care in 
compliance with the institutional animal care guidelines 
and the Guide for Care and Use of Laboratory Animals 
published by the National Institutes of Health. Mice 
were injected with streptozotocin (STZ; Amresco, USA; 
60 mg/kg/d × 5 d, i.p.) dissolved in 0.1 mM sodium cit-
rate buffer (pH 4.5). Random blood glucose was meas-
ured by using the blood glucose monitoring system 
(MAJOR, Taiwan) with whole blood from the mouse 
tail vein. On day 21, mice with the random blood glu-
cose value ≥300  mg/dL were defined as STZ-induced 
diabetic mice, which were subsequently divided into two 
groups: treated with metformin (250 mg/kg/d × 14 d, i.g., 
n = 26) or vehicle (0.5 % CMC-Na × 14 d, i.g., n = 26); 
age-matched mice without STZ treatment served as the 
control also received vehicle (0.5 % CMC-Na × 14 d, i.g., 
n =  26). On day 35, mice were used for wound healing 
experiment, or anesthetized to harvest bone marrow to 
isolate EPCs (Fig. 1).
Evaluation of wound healing and angiogenesis
Mice were anesthetized with ketamine (100 mg/kg, i.p.), 
and fixed to remove hair on the dorsum by swabbing with 
betadine and 75 % ethanol before wounding [29]. A 6 mm 
circular wound was made by punch biopsy, and closure 
of the wounded area was measured every 2  days until 
day 10. The wound area was digitized and areas were 
calculated.
Skin at the wounded area was harvested on day 3, 6 
and 9 after punch biopsy. Evaluation of angiogenesis was 
conducted by CD31 immunochemistry and hematoxylin 
staining [29, 30]. Capillaries were recognized as tubular 
structures positive for CD31. One slide from each mouse 
was examined under high-power fields.
Determination of circulating EPCs
About 0.5  ml blood was harvested from anesthetized 
mice, and were dissolved in PBS (1:1). The samples were 
added into 1  ml gradient centrifugation liquid 10831 
(Sigma, St. Louis, MO, USA) gently, and followed by 
3000  rpm centrifugation for 25  min. The cell layer was 
extracted and underwent 5 min lysis of erythrocyte. The 
samples were incubated with FITC-Sca-1 (BD, San Diego, 
CA, USA) and PE-Flk-1 (BD, San Diego, CA, USA) anti-
bodies for flow cytometry examination [29].
Assessment of BM‑EPC functions
BM-EPCs from C57BL/6 mice were isolated, cultured 
and identified as previously described [31]. To confirm 
the BM-EPCs phenotypes, cells were stained for the 
uptake of Dil-acLDL (Molecular Probes Inc., Eugene, OR, 
USA) and FITC-labeled Ulex europaeus agglutinin (lec-
tin; Sigma-Aldrich, St. Louis, MO, USA). The abilities of 
tube formation and migration of BM-EPCs were deter-
mined to assess EPC functions. The angiogenic capacity 
of BM-EPCs was determined by Matrigel tube forma-
tion assay. Briefly, BM-EPCs were isolated and cultured 
Fig. 1 Illustration of experimental protocols. STZ (60 mg/kg/d × 5 d, 
i.p.) was given to induce diabetes in C57BL/6 mice, and blood glucose 
was monitored. Metformin (250 mg/kg/d × 14 d, i.g.) was given for 
consecutive 14 days. Then wound healing, BM‑EPC functions and 
proteins were measured
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for 7 days, and were harvested using 0.125 % trypsin. The 
cells with a concentration of 5 × 104/100 μl were plated 
to a 96-well plate pre-coated with 50  μl/well growth 
factor-induced Matrigel (BD Biosciences, Bedford, MA, 
USA). After 6 h incubation at 37 °C, tube formation abil-
ity of BM-EPCs was evaluated by counting tube num-
bers. Images of tube morphology were taken under the 
inverted phase contrast microscope.
The migratory ability of EPCs was assessed by a modi-
fied Boyden chamber assay. The cells with a concentra-
tion of 5 × 104/100 μl were plated on the upper chamber 
with polycarbonate membrane (8 μm pores), and VEGF 
(50  ng/ml) was added to the cell-free medium in lower 
chamber of a 24-well Transwell plate (Corning Transwell, 
Lowell, MA, USA). After incubation at 37  °C for 24  h, 
cells were fixed with 2 % paraformaldehyde, and stained 
by Hoechst 33258 (10  μg/ml). The migrated cells were 
observed under the fluorescence microscope.
Determination of SDF‑1α protein by ELISA
The serum concentration of SDF-1α protein in mice after 
metformin treatment was determined by ELISA (R&D 




BM-EPCs were isolated from male C57BL/6 mice, and 
cultured for 7 days. Medium were replaced with high glu-
cose (HG, 33 mM, M199 containing 27.5 mM d-glucose) 
medium or high glucose medium containing metformin 
(2 mM) for 24 h [32]. The basal M199 containing 5.5 mM 
glucose (normal glucose, NG) was served as control, 
and M199 containing 27.5 mM mannitol was used as an 
osmotic control (Mtol). In addition, metformin (2  mM) 
or compound C (10  μM) was added into the medium 
alone and maintained for 24 h to see the basal effects of 
the compounds. Effects of metformin on high glucose 
induced EPCs dysfunction were assessed by functional 
analysis.
Measurement of AMPK and eNOS expression
The samples were prepared as described previously [33]. 
Protein concentrations were quantified by the BCA 
Protein Assay Kit (Thermo, Rockford, USA). Samples 
containing equal amounts of protein were subjected to 
SDS-PAGE in a Bio-Rad miniature slab gel apparatus 
and electrophoretically transferred onto a nitrocellu-
lose membrane. The membranes were incubated with 
5  % BSA/PBST for 1  h at 25  °C, and incubated over-
night at 4  °C with primary antibodies and 1  h at 25  °C 
with secondary antibodies respectively. Cell Signal-
ing Technology Inc (Danvers, Mass) was the supplier 
for the following primary antibodies: rabbit polyclonal 
anti-phospho-eNOS (Ser1177) antibody, rabbit anti-
phospho-AMPK (Thr172) antibody, rabbit anti-AMPK 
antibody. Mouse anti-eNOS monoclonal antibody was 
obtained from BD Transduction Laboratories (Lexing-
ton, Ky).
Detection of intracellular NO
Intracellular NO level was detected by membrane-per-
meable probes DAF-FM diacetate (Invitrogen, Carlsbad, 
CA). Briefly, 7  days after BM-EPCs isolation, the cells 
were harvested using 0.125 % trypsin. After suspension, 
the samples were incubated with DAF-FM diacetate 
(10−6  mol/L) for 30  min at 37  °C and 30  min at room 
temperature in dark respectively for flow cytometry 
examination.
Statistical analysis
Data are presented as mean  ±  SEM. Statistical analy-
sis was performed by one-way analysis of variance 
(ANOVA) with Newman–Keuls multiple comparison 
test. A value of P < 0.05 was considered to be statistically 
significant.
Results
Body weight and blood glucose changes in diabetic mice
Blood glucose in STZ-induced diabetic mice was signif-
icantly increased (384 ± 10 vs 162 ± 8 mg/dl, P < 0.05; 
Fig.  2a), while body weight was significantly decreased 
when compared with the control after STZ injection on 
day 20 (19 ±  0.4 vs 24 ±  0.6 g, P < 0.05; Fig. 2b). Met-
formin treatment for consecutive 14  days significantly 
decreased the blood glucose level, but did not modify 
the body weight in STZ-induced diabetic mice (P < 0.01; 
Fig. 2c, d).
Metformin accelerated wound closure and angiogenesis 
in diabetic mice
To assess the effects of metformin on wound healing in 
STZ-induced diabetic mice, the percentage of wound clo-
sure was measured every other day until day 10. Wound 
healing was significantly slowed in STZ-induced diabetic 
mice when compared to the control, and metformin sig-
nificantly accelerated the wound closure (P < 0.05; Fig. 3a, 
b) in diabetic mice.
The number of CD31-positive tubular structures in the 
wounds and surrounding skin were calculated to further 
evaluate the role of metformin on neovascularization. 
Capillary formation in STZ-induced diabetic mice was 
significantly worse on day 3, 6 and 9 when compared 
to control. However, metformin significantly improved 
the capillary formation in diabetic mice on day 6 and 9 
(P < 0.05, Fig. 3c, d).
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Fig. 2 Establishment of STZ‑induced diabetic mice. Compared with the control, mice treated with STZ (60 mg/kg/d × 5 d, i.p.) displayed higher 
blood glucose (a) and lower body weight (b). Metformin (250 mg/kg/d × 14 d, i.g.) decreased blood glucose (c), but did not change the body 
weight (d) in STZ‑induced diabetic mice. **P < 0.01, *P < 0.05 vs Control; ##P < 0.01 vs STZ. Values are mean ± SEM (n = 10 per group)
Fig. 3 Metformin accelerated wound healing and stimulated angiogenesis in diabetic mice. Six‑mm diameter wound was made by punch biopsy 
and closure of the wound area was measured every 2 days until day 10, metformin accelerated wound closure in STZ‑induced diabetic mice (a, b). 
Typical photographs of CD31‑positive staining on the wounded area were obtained on day 3, 6 and 9 (c, d). **P < 0.01, *P < 0.05 vs Control; #P < 0.05 
vs STZ. Values are mean ± SEM (n = 5 per group)
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Metformin improved BM‑EPC functions in diabetic mice
To test that metformin increased the capillary densi-
ties by improving the angiogenic functions of EPCs in 
STZ-induced diabetic mice, the capacities of tube for-
mation and migration of BM-EPCs were assessed. It was 
found that functions of BM-EPCs in diabetic mice were 
significantly lower compared to control. Metformin 
significantly increased both the capacities of tube forma-
tion (0.70 ± 0.04 vs 0.54 ± 0.04, P < 0.05; Fig. 4a, b) and 
migration (0.66 ± 0.08 vs 0.37 ± 0.06, P < 0.05; Fig. 4c, d) 
in STZ-induced diabetic mice. Moreover, metformin sig-
nificantly increased circulating EPCs in STZ-induced dia-
betic mice (2.18 ± 0.32 vs 1.11 ± 0.18 %, P < 0.05; Fig. 4e, 
f ). In addition, we found that the serum concentration of 
SDF-1α protein was not changed after metformin treat-
ment (Additional file 1: Figure S1).
Metformin alleviated high glucose‑induced dysfunction 
of BM‑EPCs in vitro
BM-EPCs from C57BL/6 mice were identified as Dil-
acLDL and lectin double-positive cells under a fluo-
rescence microscope (Additional file  2: Figure S2). To 
investigate whether the effect of metformin on EPCs in 
diabetic mice was directly related to the high glucose, 
high glucose was used to induce BM-EPC dysfunction 
in  vitro. High glucose significantly decreased both the 
capacities of tube formation and migration in cultured 
BM-EPCs compared to the control. Metformin improved 
impaired BM-EPC functions caused by high glucose 
(Tube formation: 0.80 ± 0.03 vs 0.62 ± 0.03; Migration: 
1.04  ±  0.12 vs 0.59  ±  0.03, P  <  0.05; Fig.  5). However, 
compared with the NG,  BM-EPCs treated with manni-
tol (served as the osmotic control for the HG) showed 
no significant changes in tube formation and migration 
(Additional file 3: Figure S3).
Metformin increased both AMPK and eNOS 
phosphorylated‑to‑total ratio in BM‑EPCs in diabetic mice
Expression of AMPK and eNOS in BM-EPCs of STZ-
induced diabetic mice was determined. Western blot 
analysis found that total AMPK and eNOS protein in 
BM-EPCs showed no difference among groups. How-
ever, both phosphorylated-AMPK and phosphoryl-
ated-eNOS expression in BM-EPCs were decreased in 
STZ-induced diabetic mice compared to the control. 
Metformin increased both phosphorylated-AMPK 
and phosphorylated-eNOS expression in BM-EPCs of 
the diabetic mice (P  <  0.05; Fig.  6). Meanwhile, it was 
found that the intracellular NO level in BM-EPCs was 
significantly decreased in STZ-induced diabetic mice, 
and metformin increased the intracellular NO level 
(P < 0.05; Fig. 6).
Metformin increased phosphorylated‑eNOS in BM‑EPCs 
via an AMPK dependent pathway in vitro
To explore whether expression of phosphorylated eNOS 
was determined by activation of AMPK, phosphorylated-
eNOS expression in BM-EPCs in  vitro was measured 
when AMPK inhibitor was used. Similarly, high glucose 
induced decreased phosphorylated-eNOS in  vitro, and 
metformin significantly prevented the change caused by 
high glucose. Importantly, inhibition of AMPK by com-
pound C significantly inhibited phosphorylated-eNOS 
expression enhanced by metformin in BM-EPCs cul-
tured in  vitro (P  <  0.05; Fig.  7). In addition, metformin 
reversed intracellular NO production caused by high 
glucose, which was prevented by inhibiting AMPK with 
compound C (P < 0.05; Fig. 7). Metformin alone did not 
change BM-EPC functions of both tube formation and 
migration, while compound C significantly inhibited tube 
formation, but not migration (Additional file 4: Figure S4).
Discussion
In the present study, we found that: (1) metformin accel-
erated wound healing and stimulated angiogenesis, 
improved the impaired EPC capacity, and increased NO 
production in BM-EPCs of STZ-induced diabetic mice; 
(2) In vitro, metformin improved high glucose-impaired 
EPC function, and enhanced intracellular NO level; (3) 
the protective effects of metformin on BM-EPCs were 
possibly related to activating AMPK/eNOS pathway.
Wound healing involves an integrative interplay of 
cells, mediators, growth factors, and cytokines, which is 
responded to tissue injury [34, 35]. Under diabetic con-
dition, impaired wound healing and reduced vascular 
repair may be a consequence of a metabolic derangement 
[34, 36, 37]. In addition, chronic hyperglycemia has been 
reported to be responsible for the onset of microvascular 
complications, including the diabetic foot ulcer and risk 
for amputation [38]. Angiogenesis plays a significant role 
in skin maintenance and repair, depending on various cell 
participation and coordination, especially EPCs [39, 40]. 
However, much of the complexity of the angiogenesis has 
not yet to be defined [34].
Metformin is one of the most widely used drugs for 
the treatment of type 2 diabetes, which improves vas-
cular endothelial functions in type 2 diabetic patients, 
although its mechanisms remain largely unknown [41]. 
Recently, several studies showed the paradoxical effects 
of metformin on the angiogenesis. In general, metformin 
was considered to down-regulate tumor angiogenesis [42, 
43]. However, in disease models such as heart failure and 
diabetes, metformin was associated with enhanced angi-
ogenesis  [12, 44,  45]. It was also found that metformin 
prevented partially insulin-deficient diabetes-induced 
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bone microarchitecture alterations [46], and enhance the 
process of bone repair in diabetic and nondiabetic rats 
[47]. Other anti-diabetic drugs, such as dipeptidyl pepti-
dase-4 (DPP-4) and alpha-glucosidase inhibitor could 
also improve endothelial function in patients with type 
2 diabetes [48], rosiglitazone could improve angiogenic 
potential of diabetic ECs and proangiogenic cells (PACs) 
[49]. In our work, we found that metformin (250  mg/
kg/d × 14 d, i.g.) did increase the capillary densities and 
the percentage of wound closure in STZ-induced diabetic 
mice. Thus, we further explored the effect of metformin 
on BM-EPC functions in STZ-induced diabetic mice.
Endothelial monolayer is necessary for preserving 
the integrity of vasculature [50]. The functional activity 
and even the structure of endothelial cells are impaired 
under diabetic conditions, which may contribute to 
microvascular and macrovascular abnormalities [51]. 
EPCs, a group of multi-progenitor cells, can differenti-
ate into endothelial cells, and make up the lining of blood 
vessels [52]. EPCs are important precursors of endothelial 
cell, and it has been shown that EPCs were involved in 
angiogenesis and wound repair in diabetic patients [53–
55]. Importantly, systematic administration of EPCs could 
significantly improve angiogenesis and wound healing 
in a mouse model of type 2 diabetes [56]. These suggest 
that improvement of EPC function or increase of circulat-
ing EPCs might be clinically significance with treatment 
of certain specific drugs, especially for diabetic vascular 
complications. It was found that the percentage of circu-
lating EPCs and functions of BM-EPCs in diabetic mice 
were significantly lower compared with the control. Met-
formin treatment significantly prevented these changes in 
Fig. 4 Metformin improved BM‑EPC functions in diabetic mice. BM‑EPCs from anesthetized mice were isolated and cultured. Metfromin improved 
the tube formation (a, b) and migration (c, d) ability of BM‑EPCs. Blood was harvested from anesthetized mice. Metformin increased circulating EPCs 
in STZ‑induced diabetic mice (e, f). **P < 0.01 vs Control; #P < 0.05 vs STZ. Values are mean ± SEM (n = 6 per group)
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Fig. 5 Metformin alleviated high glucose‑induced dysfunction of BM‑EPCs in vitro. BM‑EPCs were incubated for 24 h with high glucose (33 mM), 
or high glucose (33 mM) + metformin (2 mM). BM‑EPCs without high glucose and drug treatment were served as control. Metformin significantly 
increased high glucose‑impaired tube formation (a, b), and migration (c, d) ability in cultured BM‑EPCs in vitro. **P < 0.01, *P < 0.05 vs Control; 
#P < 0.05 vs HG. Values are mean ± SEM (n = 5 per group)
Fig. 6 Metformin improved the impaired BM‑EPCs by activating AMPK/eNOS pathway in diabetic mice. BM‑EPCs from anesthetized mice were 
isolated and cultured. AMPK and eNOS in BM‑EPCs, and intracellular NO levels were measured. Metformin significantly increased AMPK (a, b) and 
eNOS (c, d) phosphorylated‑to‑total ratio, and enhanced NO production (e, f) of BM‑EPCs from diabetic mice. **P < 0.01, *P < 0.05 vs Control; 
#P < 0.05 vs STZ. Values are mean ± SEM (a, b, c, d: n = 4 per group; e, f: n = 6 per group)
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diabetic mice. In addition, metformin treatment improved 
impaired BM-EPC function caused by high glucose. Thus, 
we postulated that the effect of metformin in accelerat-
ing wound healing under diabetic condition was possibly 
related to improving impaired BM-EPC functions and 
increasing circulating EPCs number.
Dysfunction of EPCs contributes to the pathogenesis 
of diabetes, and the main cause of EPC dysfunction is 
the loss of protection from NO due to reduced synthe-
sis from eNOS [57, 58]. One of the AMPK targets that 
may be particularly important in the circulatory system 
is the eNOS [59]. Moreover, AMPK was suggested as a 
drug target for diabetes mellitus, including drugs as met-
formin [60]. Activation of AMPK by metformin could 
protect human coronary artery endothelial cells and 
against diabetic lipoapoptosis [61]. In our work, met-
formin significantly increased both AMPK and eNOS 
phosphorylated-to-total ratio, and enhanced NO pro-
duction of BM-EPCs from diabetic mice. In  vitro, met-
fromin increased both phosphorylated-eNOS expression 
and intracellular NO levels in cultured BM-EPCs. Impor-
tantly, inhibition of AMPK by compound C prevented 
these changes by metformin. These indicated that the 
beneficial effect of metformin on BM-EPC functions 
in STZ-induced diabetic mice was related to activating 
AMPK/eNOS pathway.
Conclusions
In summary, our work demonstrated that metformin 
could accelerate wound healing, stimulate angiogen-
esis, improve the impaired BM-EPC functions, and 
increase both phosphorylated-AMPK and phosphoryl-
ated-eNOS expression in BM-EPCs from STZ-induced 
diabetic mice. In  vitro, metformin could improve high 
glucose-impaired BM-EPC functions, and increase 
phosphorylated-eNOS expression and NO production 
in BM-EPCs caused by high glucose. These together 
suggest that metformin may improve BM-EPC func-
tions in diabetic mice possibly with an AMPK/eNOS 
dependent pathway.
Fig. 7 Metformin increased phosphorylated‑eNOS in BM‑EPCs via an AMPK dependent pathway in vitro. Metformin (2 mM) and compound 
C (10 μM) were added into the high glucose medium for 24 h. Metfromin significantly increased high glucose‑induced phosphorylated‑eNOS 
expression (a, b) and intracellular NO levels (c, d) in cultured BM‑EPCs. Inhibition of AMPK by compound C significantly downregulated phospho‑
rylated‑eNOS expression (a, b) and NO production (c, d) enhanced by metformin in BM‑EPCs cultured in vitro. *P < 0.05 vs Control; #P < 0.05 vs HG; 
&P < 0.05 vs HG + Met. Values are mean ± SEM (a, b: n = 3 per group; c, d: n = 5 per group)
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